Thursday 17 March 2016

Sun Pharma's arm Taro plans shares repurchase worth US$ 250mn

Repurchases may be made from time to time at the company's discretion, based on ongoing assessments of the capital needs of the business, the market price of its stock, and general market conditions, the company reportedly said. 

Taro Pharmaceutical Industries reportedly said that its board of directors has approved a $250-mn share repurchase of its ordinary shares.

Repurchases may be made from time to time at the company's discretion, based on ongoing assessments of the capital needs of the business, the market price of its stock, and general market conditions, the company reportedly said.

The company stated that no time period has been set for the repurchase programme, and any such programme may be suspended or discontinued at any time.

Sun Pharmaceuticals Industries Ltd ended at Rs. 836.65, down by Rs. 7.25 or 0.86% from its previous closing of Rs. 843.9 on the BSE.

The scrip opened at Rs. 845 and touched a high and low of Rs. 849 and Rs. 822.5 respectively. A total of 2793426(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 201358.94 crore.

The BSE group 'A' stock of face value Rs. 1 touched a 52 week high of Rs. 1200.7 on 07-Apr-2015 and a 52 week low of Rs. 706.4 on 24-Nov-2015. Last one week high and low of the scrip stood at Rs. 876 and Rs. 822.5 respectively.

The promoters holding in the company stood at 54.97 % while Institutions and Non-Institutions held 35.25 % and 9.77 % respectively.

The stock traded below its 200 DMA.

No comments:

Post a Comment